Zigakibart

泽戈奇拜单抗

Report date: 2026/05/07 20:00:36

Base Information

Drug NameZigakibart
Drug Alias NameBION-1301FUB523FUB-523
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 inhibitors
TargetsTumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsProteinuriaGlomerulonephritis, IGAMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[23] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAduro Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovartis AgSanReno Therapeutics (Shanghai) LtdNovartis Pharma Ag +[5] 
Inactive CompaniesN/A
Active IndicationsProteinuriaGlomerulonephritis, IGA
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A